# Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer

> **NCT03412994** · PHASE2 · UNKNOWN · sponsor: **Liqiang Zhong** · enrollment: 60 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Apatinib
- **DRUG:** standard second-line chemotherapy

## Key facts

- **NCT ID:** NCT03412994
- **Lead sponsor:** Liqiang Zhong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-28
- **Primary completion:** 2020-02-28
- **Final completion:** 2021-02-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2018-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03412994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03412994, "Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03412994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*